Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include novel drugs that offer new treatment options, as well as first generics and ...

The Association for Accessible Medicines and its Biosimilars Council have released an analysis undertaken by the IQVIA Institute for Human Data Science on behalf of AAM assessing the impact of patent ...

The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...

According to the Association for Accessible Medicine’s 2024 U.S. Generic and Biosimilar Medicines Savings Report, the use of Food and Drug Administration-approved generic and biosimilar medicines ...

This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American Even if you have never heard of biosimilar ...

LONDON, May 25 (Reuters) - Israel's Teva Pharmaceutical Industries is developing a generic version of Roche's blockbuster antibody drug Rituxan, highlighting the race to produce so-called biosimilar ...

Revenues from new products helped LLY offset sagging sales of established blockbuster drugs. Lilly's blockbuster drugs are facing patent cliffs and generic competitions. Basaglar, a biosimilar version ...

The settlement terms cover a broad release of claims, spanning the alleged conduct period from 2009 to 2019 and all medicines. Class members retain the option to opt-out, potentially reducing the ...

Both Alvotech ALVO and Teva Pharmaceuticals TEVA operate in the biosimilar space, but their business models differ significantly. ALVO has built its revenue model around partnerships, relying on ...